QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
(State or Other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification Number) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
☑ | No |
☑ | No |
Yes | ☐ | No |
Page | ||||||||
Item 1. | ||||||||
Condensed Consolidated Balance Sheets - March 31, 2024 (unaudited) and December 31, 2023 | ||||||||
Condensed Consolidated Statements of Comprehensive Loss (unaudited) - Three Months Ended March 31, 2024 and 2023 | ||||||||
Condensed Consolidated Statements of Stockholders’ Equity (unaudited) - Three Months Ended March 31, 2024 and 2023 | ||||||||
Condensed Consolidated Statements of Cash Flows (unaudited) - Three Months Ended March 31, 2024 and 2023 | ||||||||
Notes to Condensed Consolidated Financial Statements (unaudited) | ||||||||
Item 2. | ||||||||
Item 3. | ||||||||
Item 4. | ||||||||
Item 1. | ||||||||
Item 1A. | ||||||||
Item 2. | ||||||||
Item 5. | ||||||||
Item 6. | ||||||||
As of March 31, | As of December 31, | |||||||||||||
2024 | 2023 | |||||||||||||
Assets | (unaudited) | |||||||||||||
Current assets: | ||||||||||||||
Cash and cash equivalents | $ | $ | ||||||||||||
Short-term investments | ||||||||||||||
Accounts receivable, net | ||||||||||||||
Inventory | ||||||||||||||
Prepaid expenses and other current assets | ||||||||||||||
Total current assets | ||||||||||||||
Property and equipment, net of accumulated depreciation and amortization of $ | ||||||||||||||
Goodwill | ||||||||||||||
Operating lease right-of-use-assets | ||||||||||||||
Other assets | ||||||||||||||
Total assets | $ | $ | ||||||||||||
Liabilities and Stockholders’ Equity | ||||||||||||||
Current liabilities: | ||||||||||||||
Accounts payable | $ | $ | ||||||||||||
Accrued liabilities | ||||||||||||||
Total current liabilities | ||||||||||||||
Long-term debt, net | ||||||||||||||
Long-term operating lease liabilities | ||||||||||||||
Total liabilities | ||||||||||||||
Commitments and contingencies (Note 6) | ||||||||||||||
Stockholders’ Equity: | ||||||||||||||
Preferred stock, $ | ||||||||||||||
Series A Convertible preferred stock, | ||||||||||||||
Common stock, $ | ||||||||||||||
Additional paid-in capital | ||||||||||||||
Accumulated deficit | ( | ( | ||||||||||||
Accumulated other comprehensive income/(loss) | ( | |||||||||||||
Treasury stock, at cost, | ( | ( | ||||||||||||
Total stockholders’ equity | ||||||||||||||
Total liabilities and stockholders’ equity | $ | $ |
Three Months Ended March 31, | |||||||||||
2024 | 2023 | ||||||||||
Revenues: | |||||||||||
Net product revenue | $ | $ | |||||||||
Royalties and other revenue | |||||||||||
Total revenues | |||||||||||
Operating expenses: | |||||||||||
Cost of sales | |||||||||||
Research and development, including stock-based compensation of $ | |||||||||||
Selling, general and administrative, including stock-based compensation of $ | |||||||||||
Total operating expenses | |||||||||||
Loss from operations | ( | ( | |||||||||
Interest and other expense | ( | ( | |||||||||
Interest income and other, net | |||||||||||
Net loss | $ | ( | $ | ( | |||||||
Net loss per common share, basic and diluted | $ | ( | $ | ( | |||||||
Shares used in computing net loss per common share, basic and diluted | |||||||||||
Other comprehensive loss: | |||||||||||
Unrealized (loss) gain on investments | ( | ||||||||||
Comprehensive loss | $ | ( | $ | ( | |||||||
Common Stock | Preferred Stock | Additional | Accumulated Other | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares | Par Value | Shares | Par Value | Paid-In Capital | Accumulated Deficit | Comprehensive Gain (Loss) | Treasury Stock | Total | ||||||||||||||||||||||||||||||||||||||||||||||||
Balance at December 31, 2022 | $ | $ | $ | $ | ( | $ | ( | $ | ( | $ | ||||||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock under Equity Incentive Plans | — | — | ( | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||
Repurchase of common stock | — | — | — | — | — | — | — | ( | ( | |||||||||||||||||||||||||||||||||||||||||||||||
Net loss | — | — | — | — | — | ( | — | — | ( | |||||||||||||||||||||||||||||||||||||||||||||||
Unrealized gain (loss) on investments | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||
Balance at March 31, 2023 | $ | $ | $ | $ | ( | $ | ( | $ | ( | $ | ||||||||||||||||||||||||||||||||||||||||||||||
Common Stock | Preferred Stock | Additional | Accumulated Other | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares | Par Value | Shares | Par Value | Paid-In Capital | Accumulated Deficit | Comprehensive Gain (Loss) | Treasury Stock | Total | ||||||||||||||||||||||||||||||||||||||||||||||||
Balance at December 31, 2023 | $ | $ | $ | $ | $ | ( | $ | $ | ( | $ | ||||||||||||||||||||||||||||||||||||||||||||||
Stock-based compensation | — | — | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of preferred stock, net of fees | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||
Issuance of common stock under Equity Incentive Plans | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||||
Repurchase of common stock | — | — | — | — | — | — | — | ( | ( | |||||||||||||||||||||||||||||||||||||||||||||||
Net loss | — | — | — | — | — | ( | — | — | ( | |||||||||||||||||||||||||||||||||||||||||||||||
Unrealized gain (loss) on investments | — | — | — | — | — | — | ( | — | ( | |||||||||||||||||||||||||||||||||||||||||||||||
Balance at March 31, 2024 | $ | $ | $ | $ | ( | $ | ( | $ | ( | $ | ||||||||||||||||||||||||||||||||||||||||||||||
Three Months Ended March 31, | ||||||||||||||
2024 | 2023 | |||||||||||||
Cash flows from operating activities: | ||||||||||||||
Net loss | $ | ( | $ | ( | ||||||||||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||||||||
Depreciation and amortization | ||||||||||||||
Stock-based compensation | ||||||||||||||
Amortization of debt-related costs | ||||||||||||||
Other non-cash adjustments | ( | |||||||||||||
Changes in operating assets and liabilities: | ||||||||||||||
Increase in accounts receivable | ( | ( | ||||||||||||
Increase in inventories | ( | |||||||||||||
Increase in prepaid expenses and other current assets | ( | ( | ||||||||||||
Decrease in other long-term assets | ||||||||||||||
Decrease in accounts payable and other liabilities | ( | ( | ||||||||||||
Net cash used in operating activities | ( | ( | ||||||||||||
Cash flows from investing activities: | ||||||||||||||
Purchases of property and equipment | ( | |||||||||||||
Purchases of investments | ( | ( | ||||||||||||
Maturities of investments | ||||||||||||||
Net cash (used in) provided by investing activities | ( | |||||||||||||
Cash flows from financing activities: | ||||||||||||||
Proceeds from issuance of common stock for equity incentive plans | ||||||||||||||
Proceeds from issuance of preferred stock, net of fees | ||||||||||||||
Repurchase of common stock for equity incentive plans | ( | ( | ||||||||||||
Other | ( | |||||||||||||
Net cash provided by (used in) financing activities | ( | |||||||||||||
Net increase (decrease) in cash and cash equivalents | ( | |||||||||||||
Cash and cash equivalents at beginning of period | ||||||||||||||
Cash and cash equivalents at end of period | $ | $ | ||||||||||||
Supplemental disclosure of cash flow information: | ||||||||||||||
Cash paid for interest | $ | $ | ||||||||||||
Supplemental disclosure of non-cash investing and financing activities: | ||||||||||||||
Accrued financing costs | $ | $ | ||||||||||||
As of March 31, 2024 | ||||||||||||||||||||||||||
Amortized Cost | Gross Unrealized Gains | Gross Unrealized Losses | Estimated Fair Value | |||||||||||||||||||||||
(in thousands) | ||||||||||||||||||||||||||
Cash and cash equivalents | $ | $ | $ | $ | ||||||||||||||||||||||
Securities maturing within one year: | ||||||||||||||||||||||||||
U.S. treasury securities | ( | |||||||||||||||||||||||||
Corporate debt securities | ( | |||||||||||||||||||||||||
Total short-term investments | $ | $ | $ | ( | $ | |||||||||||||||||||||
Total cash and cash equivalents and investments | $ | $ | $ | ( | $ | |||||||||||||||||||||
As of December 31, 2023 | ||||||||||||||||||||||||||
Amortized Cost | Gross Unrealized Gains | Gross Unrealized Losses | Estimated Fair Value | |||||||||||||||||||||||
(in thousands) | ||||||||||||||||||||||||||
Cash and cash equivalents | $ | $ | $ | $ | ||||||||||||||||||||||
Securities maturing within one year: | ||||||||||||||||||||||||||
U.S. treasury securities | ( | |||||||||||||||||||||||||
Corporate debt securities | ||||||||||||||||||||||||||
Total short-term investments | $ | $ | $ | ( | $ | |||||||||||||||||||||
Total cash and cash equivalents and investments | $ | $ | $ | ( | $ |
Assets at Fair Value as of March 31, 2024 | ||||||||||||||||||||||||||
Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||||||
(in thousands) | ||||||||||||||||||||||||||
Cash and cash equivalents | $ | $ | $ | $ | ||||||||||||||||||||||
Short-term investments | ||||||||||||||||||||||||||
Total cash and cash equivalents and investments | $ | $ | $ | $ |
Assets at Fair Value as of December 31, 2023 | ||||||||||||||||||||||||||
Level 1 | Level 2 | Level 3 | Total | |||||||||||||||||||||||
(in thousands) | ||||||||||||||||||||||||||
Cash and cash equivalents | $ | $ | $ | $ | ||||||||||||||||||||||
Short-term investments | ||||||||||||||||||||||||||
Total cash and cash equivalents and investments | $ | $ | $ | $ | ||||||||||||||||||||||
As of March 31, | As of December 31, | |||||||||||||
2024 | 2023 | |||||||||||||
(in thousands) | ||||||||||||||
Inventories: | ||||||||||||||
Raw materials | $ | $ | ||||||||||||
Work-in-progress | ||||||||||||||
Finished goods | ||||||||||||||
Inventory | $ | $ |
As of March 31, | As of December 31, | |||||||||||||
2024 | 2023 | |||||||||||||
(in thousands) | ||||||||||||||
Accrued Liabilities: | ||||||||||||||
Accrued research and development services | $ | $ | ||||||||||||
Accrued compensation and benefits | ||||||||||||||
Short-term lease liability | ||||||||||||||
Other | ||||||||||||||
Total accrued liabilities | $ | $ |
(in thousands) | |||||
2024 | $ | ||||
2025 | |||||
2026 | |||||
2027 | |||||
2028 | |||||
Thereafter | |||||
Total undiscounted operating lease liability | |||||
Less: amount of lease payments representing interest | ( | ||||
Present value of future lease payments | |||||
Less: short-term operating lease liability | ( | ||||
Long-term operating lease liability | $ |
Expected Volatility | Risk-free Interest Rate | Expected Term | Dividend Rate | |||||||||||||||||||||||
March 31, 2024 | ||||||||||||||||||||||||||
Employees | % | % | % | |||||||||||||||||||||||
Officers and non-employee directors | % | % | % | |||||||||||||||||||||||
March 31, 2023 | ||||||||||||||||||||||||||
Employees | % | % | % | |||||||||||||||||||||||
Officers and non-employee directors | % | % | % |
Stock Options | Weighted Average Exercise Price | |||||||||||||
(in thousands) | ||||||||||||||
Outstanding at December 31, 2023 | $ | |||||||||||||
Granted | ||||||||||||||
Exercised | ( | |||||||||||||
Expired | ( | |||||||||||||
Forfeited | ( | |||||||||||||
Outstanding at March 31, 2024 | ||||||||||||||
Exercisable at March 31, 2024 | $ |
RSU’s | Weighted Average Grant Date Fair Value | |||||||||||||
(in thousands) | ||||||||||||||
Outstanding at December 31, 2023 | $ | |||||||||||||
Granted | ||||||||||||||
Vested | ( | |||||||||||||
Forfeited | ( | |||||||||||||
Outstanding at March 31, 2024 | $ |
Three Months Ended March 31, | ||||||||||||||
2024 | 2023 | |||||||||||||
Total research and development expense | $ | 14.4 | $ | 12.0 | ||||||||||
Dollar increase | $ | 2.4 | ||||||||||||
Percentage increase | 20 | % |
Three Months Ended March 31, | |||||||||||||||||
2024 | 2023 | ||||||||||||||||
Total selling, general and administrative expense | $ | 32.1 | $ | 19.1 | |||||||||||||
Dollar increase | $ | 13.0 | |||||||||||||||
Percentage increase | 68 | % |
Period | Total Number of Shares Purchased | Average Price Paid Per Share | Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs | Maximum Number of Shares that May Yet be Purchased Under the Plans or Programs (3) | ||||||||||||||||||||||
January 1-31, 2024 | — | $ | — | — | — | |||||||||||||||||||||
February 1-29, 2024 | 660,039 | (1) | $ | 2.62 | (2) | — | — | |||||||||||||||||||
March 1-31, 2024 | — | $ | — | — | — |
Exhibit No. | Description | |||||||
*31.1 | — | |||||||
*31.2 | — | |||||||
*32.1 | — | |||||||
101.INS | — | XBRL Instance Document | ||||||
101.SCH | — | XBRL Taxonomy Extension Schema Document | ||||||
101.CAL | — | XBRL Taxonomy Extension Calculation Linkbase Document | ||||||
101.DEF | — | XBRL Taxonomy Extension Definition Linkbase Document | ||||||
101.LAB | — | XBRL Taxonomy Extension Label Linkbase Document | ||||||
101.PRE | — | XBRL Taxonomy Extension Presentation Linkbase Document | ||||||
104 | — | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
* | Filed herewith. | ||||
Lexicon Pharmaceuticals, Inc. | |||||||||||
Date: | May 2, 2024 | By: | /s/ Lonnel Coats | ||||||||
Lonnel Coats | |||||||||||
Chief Executive Officer |
Date: | May 2, 2024 | By: | /s/ Jeffrey L. Wade | ||||||||
Jeffrey L. Wade | |||||||||||
President and Chief Financial Officer |
/s/ Lonnel Coats | |||||
Lonnel Coats | |||||
Chief Executive Officer |
/s/ Jeffrey L. Wade | ||
Jeffrey L. Wade | ||
President and Chief Financial Officer |
By: | /s/ Lonnel Coats | ||||
Lonnel Coats | |||||
Chief Executive Officer |
By: | /s/ Jeffrey L. Wade | ||||
Jeffrey L. Wade | |||||
President and Chief Financial Officer |
Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands |
Mar. 31, 2024 |
Dec. 31, 2023 |
---|---|---|
Statement of Financial Position [Abstract] | ||
Accumulated depreciation and amortization, property and equipment | $ 4,682 | $ 4,538 |
Preferred stock, par value (in dollars per share) | $ 0.01 | $ 0.01 |
Preferred stock, authorized (in shares) | 5,000,000,000 | 5,000,000,000 |
Preferred stock, issued (in shares) | 2,304,147 | 0 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, authorized (in shares) | 300,000,000 | 300,000,000 |
Common stock, issued (in shares) | 247,764,761 | 245,792,668 |
Treasury stock (in shares) | 1,528,008 | 867,973 |
Condensed Consolidated Statements of Comprehensive Loss (Parenthetical) - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Stock-based compensation | $ 4,302 | $ 3,415 |
Research and Development Expense | ||
Stock-based compensation | 1,594 | 1,203 |
Selling, General and Administrative Expenses | ||
Stock-based compensation | $ 2,708 | $ 2,212 |
Summary of Significant Accounting Policies |
3 Months Ended |
---|---|
Mar. 31, 2024 | |
Accounting Policies [Abstract] | |
Summary of Significant Accounting Policies | Summary of Significant Accounting Policies Basis of Presentation. The accompanying unaudited condensed consolidated financial statements of Lexicon Pharmaceuticals, Inc. (“Lexicon” or the “Company”) include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation. These unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three month period ended March 31, 2024 are not necessarily indicative of the results that may be expected for the year ended December 31, 2024. For further information, refer to the financial statements and footnotes thereto included in Lexicon’s annual report on Form 10-K for the year ended December 31, 2023, as filed with the SEC. Use of Estimates. The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates. Significant Accounting Policies. There have been no significant changes to our summary of significant policies discussed in our annual report on Form 10-K for the year ended December 31, 2023. Recent Accounting Pronouncements Issued But Not Yet Adopted. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280) – Improvements to Reportable Segment Disclosures, which is effective retrospectively for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) – Improvements to Income Tax Disclosures, which is effective prospectively for annual periods beginning after December 15, 2024. Early adoption is permitted for both standards. We do not expect these accounting pronouncements to have a material impact on our financial statements.
|
Cash and Cash Equivalents and Investments |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cash, Cash Equivalents, and Short-Term Investments [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cash and Cash Equivalents and Investments | Cash and Cash Equivalents and Investments The fair value of cash and cash equivalents and investments held at March 31, 2024 and December 31, 2023 are as follows:
As of March 31, 2024 and December 31, 2023, our investments in an unrealized loss position had an estimated fair value of $216.0 million and $58.5 million, respectively. There were no realized gains or losses during either of the three month periods ended March 31, 2024 and 2023.
|
Fair Value Measurements |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Measurements | Fair Value Measurements The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis. Assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value. The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities: •Level 1 - quoted prices in active markets for identical assets, which include U.S. treasury securities •Level 2 - other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.), which includes corporate debt securities •Level 3 - significant unobservable inputs The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities. The following tables provide the fair value measurements of applicable Company assets that are measured at fair value on a recurring basis according to the fair value levels defined above as of March 31, 2024 and December 31, 2023. There were no transfers between Level 1 and Level 2 during the periods presented.
|
Supplemental Financial Information |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance Sheet Related Disclosures [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Supplemental Financial Information | Supplemental Financial Information The following tables show the Company’s additional balance sheet information as of March 31, 2024 and December 31, 2023:
|
Debt Obligations |
3 Months Ended |
---|---|
Mar. 31, 2024 | |
Debt Disclosure [Abstract] | |
Debt Obligations | Debt Obligations Oxford Term Loans Overview. Lexicon and one of its subsidiaries entered into a loan and security agreement with Oxford Finance LLC (“Oxford”) in March 2022 (as subsequently amended) that provides up to $150 million in borrowing capacity (the “Oxford Term Loans”). The Oxford Term Loans are available in five tranches, each maturing in March 2027. The first two $25 million tranches totaling $50 million were funded in 2022 and the third $50 million tranche was funded in June 2023. The fourth $25 million tranche will be available for draw at Lexicon’s option upon the achievement of specified INPEFA net sales and until April 15, 2025. An unused fee will be due in the event Lexicon does not draw the full amount when available under the fourth tranche. The fifth $25 million tranche is available for draw at Lexicon’s option, subject to Oxford’s consent, at any time prior to the expiration of the interest-only period in March 2025 as described below. As of March 31, 2024, the carrying value of the Oxford Term Loans on the condensed consolidated balance sheet was $99.9 million, reflecting an unamortized discount of $6.1 million to the face value of long-term debt related to debt issuance costs, the final payment exit fee, and the warrant fair value described below, which are being amortized into interest and other expense throughout the life of the term loan using the effective interest rate method. A final payment exit fee of $6.0 million equal to 6% of the amount funded under the Oxford Term Loans is due upon prepayment or maturity. Oxford Warrants. Concurrent with the funding of each of the first three tranches, Lexicon granted Oxford warrants to purchase 420,673 shares of Lexicon’s common stock at an exercise price of $2.08 per share, 224,128 shares of Lexicon’s common stock at an exercise price of $1.95 per share and 183,824 shares of Lexicon’s common stock at an exercise price of $2.38 per share, respectively. Subject to and upon funding of the fourth tranche, Lexicon will grant Oxford a warrant to purchase shares of its common stock having a value equal to 1.75% of such tranche, as determined by reference to a 10-day average closing price of the shares, and having an exercise price equal to such average closing price. All warrants are exercisable for five years from their respective grant dates and feature a net cashless exercise provision. The Company allocated the proceeds from each term loan tranche to the corresponding warrant using the relative fair value method and used the Black-Scholes model to calculate the fair value of the warrants. These warrants reduced the carrying value of long-term debt and are classified as equity instruments in additional paid-in capital on the condensed consolidated balance sheet. Interest and Principal Payments. Monthly interest-only payments are due during an initial 36-month period from the original March 2022 borrowing date. The interest-only period will be followed by an amortization period extending through the maturity date. Payments of $34.8 million, $52.2 million, and $19.0 million, including debt principal and final exit fee payments, will be due during the fiscal years ended December 31, 2025, December 31, 2026 and December 31, 2027, respectively, with respect to all borrowed loan tranches as of March 31, 2024. Any prepayment of the Oxford Term Loans is subject to prepayment fees of up to 3% which decline over the three years following the funding date of each loan tranche. The Company has classified its debt as long-term based on its intent and ability to refinance with the recent equity financing (see Note 8) if the Company is unable to meet the financial covenants within one year. Prior to June 2023 the Oxford Term Loans bore interest at a floating rate equal to the 30-day U.S. Dollar LIBOR plus 7.90%, but not less than 8.01%, subject to additional interest if an event of default occurs and is continuing. Following the June 2023 amendment to the loan and security agreement, the floating interest rate is currently based on the sum of (a) the 1-month CME Term Secured Overnight Financing Rate (SOFR), (b) 0.10%, and (c) 7.90% for the first and second tranches and 7.00% for the third and fourth tranches. As of March 31, 2024, the weighted average interest rate of the Oxford Term Loans was 12.9%. During the three months ended March 31, 2024, the Company recognized interest expense of $3.8 million, including $0.5 million in amortization of discount and related debt issuance costs. Restrictive Provisions/Covenants. If an event of default occurs and is continuing, Oxford may declare all amounts outstanding under the loan and security agreement to be immediately due and payable. Additionally, Lexicon may prepay the Oxford Term Loans in whole at its option at any time. Lexicon’s obligations under the Oxford Term Loans are secured by a first lien security interest in all of the assets of the Company and its subsidiaries. The loan and security agreement contains certain customary representations and warranties, affirmative and negative covenants and events of default applicable to Lexicon and its subsidiaries. The loan and security agreement includes a financial covenant which requires Lexicon to maintain a minimum cash and investments balance of $10 million until the achievement of specified INPEFA net sales. Upon funding of the fourth tranche, the minimum cash and investments balance will increase to $25 million. The loan and security agreement also includes a separate financial covenant relating to net sales of INPEFA. In March 2024, this covenant was further amended and will be effective as of June 30, 2024. In addition to the financial covenants, additional covenants include those restricting dispositions, fundamental changes to its business, mergers or acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and subordinated debt. The Company was in compliance with its debt covenants as of March 31, 2024.
|
Commitments and Contingencies |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitments and Contingencies Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitments and Contingencies | Commitments and Contingencies Operating Lease Obligations. Lexicon’s operating leases include leases of office space in The Woodlands, Texas and Bridgewater, New Jersey and will expire in August 2025 and January 2034, respectively. Operating lease right-of-use assets and associated lease liabilities are recorded in the condensed consolidated balance sheet at the lease commencement date based on the present value of future lease payments to be made over the expected lease term. As the implicit rate is not determinable in its leases, Lexicon uses its incremental borrowing rate based on the information available at the commencement date to determine the present value of lease payments. Lexicon does not apply this accounting to those leases with terms of twelve months or less. As of March 31, 2024 and December 31, 2023, the right-of-use assets for the office space leases of $5.4 million and $5.5 million, respectively, are separately included in operating lease right-of-use-assets in the condensed consolidated balance sheet. Current liabilities relating to the leases were included in accrued liabilities in the condensed consolidated balance sheet (as further described in Note 4) and long-term operating lease liabilities are separately included in the condensed consolidated balance sheet. During the three months ended March 31, 2024 and 2023, the Company incurred lease expense of $0.4 million. During the three months ended March 31, 2024 and 2023, the Company made cash payments for lease liabilities of $0.3 million and $0.1 million, respectively. As of March 31, 2024 and December 31, 2023, the weighted-average remaining lease terms were 8.9 years and 9 years, respectively, with weighted-average discount rates of 9.6%. The following table reconciles the undiscounted cash flows of the operating lease liability to the recorded lease liability at March 31, 2024:
Legal Proceedings. Lexicon is from time to time party to claims and legal proceedings that arise in the normal course of its business and that it believes will not have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition or liquidity.
|
Equity Incentive Awards |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Payment Arrangement [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity Incentive Awards | Equity Incentive Awards Stock-Based Compensation. The Company has stockholder-approved equity incentive plans that permit the grant of stock options, restricted stock unit awards, and other stock-based awards to employees, directors, and consultants of the Company. Compensation expense related to stock options and restricted stock units (“RSUs”) is determined based on the fair value of the award on the date of the grant and is recognized on a straight-line basis over the vesting period in which an employee is required to provide service. Compensation expense of $4.3 million and $3.4 million for the three months ended March 31, 2024 and 2023, respectively, is recorded separately in research and development expense and selling, general, and administrative expense as noted on the Company’s condensed consolidated statements of comprehensive loss. The fair value of stock options is estimated at the date of grant using the Black-Scholes method requiring the input of subjective assumptions. Because the Company’s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management’s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination behaviors, resulting in different assumptions used for expected option lives. Historical data is used to estimate the expected option life for each group. Expected volatility is based on the historical volatility in the Company’s stock price. The following weighted-average assumptions were used for stock options granted in the three months ended March 31, 2024 and 2023:
The following is a summary of stock option activity under Lexicon’s stock-based compensation plans for the three months ended March 31, 2024:
The following is a summary of restricted stock unit activity under Lexicon’s stock-based compensation plans for the three months ended March 31, 2024:
|
Other Capital Agreements |
3 Months Ended |
---|---|
Mar. 31, 2024 | |
Equity [Abstract] | |
Other Capital Agreements | Other Capital Agreements Convertible Preferred Stock. On March 11, 2024, Lexicon entered into an agreement with certain accredited investors pursuant to which the Company agreed to sell 2,304,147 shares of its Series A Convertible Preferred Stock, par value $0.01 per share, in a private placement at a price of $108.50 per share. The Company received net proceeds of approximately $242 million, after deducting placement agent fees and offering expenses from the private placement offering. Each share of preferred stock is convertible into 50 shares of common stock following the approvals listed below. An affiliate of Invus, L.P. elected to participate on the same terms as each other purchaser on a pro rata basis and also agreed to vote at the Company’s 2024 annual meeting of stockholders in favor of the approval of an amendment to the Company’s certificate of incorporation increasing the total authorized common shares thereunder from 300,000,000 to 450,000,000 shares (the “New Charter”). Following the approval of the New Charter by the Company’s shareholders, the adoption of the New Charter by the Company’s board of directors, and the filing and acceptance of the New Charter by the Secretary of State of Delaware, each share of preferred stock will automatically convert into 50 shares (subject to adjustments) of common stock, or approximately 115 million additional common shares in total. Our convertible preferred shares, as well as other potentially dilutive securities, are not included in the calculation of diluted earnings per common share as we have reported a net loss for the three months ended March 31, 2024 and 2023, and their effect would be anti-dilutive.
|
Pay vs Performance Disclosure - USD ($) $ in Thousands |
3 Months Ended | |
---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Pay vs Performance Disclosure | ||
Net loss | $ (48,397) | $ (31,934) |
Insider Trading Arrangements |
3 Months Ended |
---|---|
Mar. 31, 2024 | |
Trading Arrangements, by Individual | |
Rule 10b5-1 Arrangement Adopted | false |
Non-Rule 10b5-1 Arrangement Adopted | false |
Rule 10b5-1 Arrangement Terminated | false |
Non-Rule 10b5-1 Arrangement Terminated | false |
Summary of Significant Accounting Policies (Policies) |
3 Months Ended |
---|---|
Mar. 31, 2024 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation. The accompanying unaudited condensed consolidated financial statements of Lexicon Pharmaceuticals, Inc. (“Lexicon” or the “Company”) include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation. These unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three month period ended March 31, 2024 are not necessarily indicative of the results that may be expected for the year ended December 31, 2024. For further information, refer to the financial statements and footnotes thereto included in Lexicon’s annual report on Form 10-K for the year ended December 31, 2023, as filed with the SEC. |
Use of Estimates | Use of Estimates. The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.
|
Significant Accounting Policies | Significant Accounting Policies. There have been no significant changes to our summary of significant policies discussed in our annual report on Form 10-K for the year ended December 31, 2023.
|
Recent Accounting Pronouncements Issued But Not Yet Adopted | Recent Accounting Pronouncements Issued But Not Yet Adopted. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280) – Improvements to Reportable Segment Disclosures, which is effective retrospectively for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740) – Improvements to Income Tax Disclosures, which is effective prospectively for annual periods beginning after December 15, 2024. Early adoption is permitted for both standards. We do not expect these accounting pronouncements to have a material impact on our financial statements.
|
Cash and Cash Equivalents and Investments (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cash, Cash Equivalents, and Short-Term Investments [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Cash, Cash Equivalents and Short-term Investments | The fair value of cash and cash equivalents and investments held at March 31, 2024 and December 31, 2023 are as follows:
|
Fair Value Measurements (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Fair Value Measurements | The following tables provide the fair value measurements of applicable Company assets that are measured at fair value on a recurring basis according to the fair value levels defined above as of March 31, 2024 and December 31, 2023. There were no transfers between Level 1 and Level 2 during the periods presented.
|
Supplemental Financial Information (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance Sheet Related Disclosures [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Inventory, Current | The following tables show the Company’s additional balance sheet information as of March 31, 2024 and December 31, 2023:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Accrued Liabilities |
|
Commitment and Contingencies (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Commitments and Contingencies Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Lessee, Operating Lease, Liability, to be Paid, Maturity | The following table reconciles the undiscounted cash flows of the operating lease liability to the recorded lease liability at March 31, 2024:
|
Equity Incentive Awards (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Payment Arrangement [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions | The following weighted-average assumptions were used for stock options granted in the three months ended March 31, 2024 and 2023:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Share-based Payment Arrangement, Option, Activity | The following is a summary of stock option activity under Lexicon’s stock-based compensation plans for the three months ended March 31, 2024:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Nonvested Restricted Stock Units Activity | The following is a summary of restricted stock unit activity under Lexicon’s stock-based compensation plans for the three months ended March 31, 2024:
|
Cash and Cash Equivalents and Investments - Narrative (Details) - USD ($) $ in Millions |
3 Months Ended | ||
---|---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
Dec. 31, 2023 |
|
Cash, Cash Equivalents, and Short-Term Investments [Abstract] | |||
Investments in an unrealized loss position, fair value | $ 216.0 | $ 58.5 | |
Realized gains (losses) | $ 0.0 | $ 0.0 |
Fair Value Measurements (Details) - USD ($) $ in Thousands |
Mar. 31, 2024 |
Dec. 31, 2023 |
---|---|---|
Fair Value | ||
Cash and cash equivalents | $ 96,494 | $ 22,465 |
Short-term investments | 259,104 | 147,561 |
Total cash and cash equivalents and investments | 355,598 | 170,026 |
Level 1 | ||
Fair Value | ||
Cash and cash equivalents | 96,494 | 22,465 |
Short-term investments | 245,098 | 141,596 |
Total cash and cash equivalents and investments | 341,592 | 164,061 |
Level 2 | ||
Fair Value | ||
Cash and cash equivalents | 0 | 0 |
Short-term investments | 14,006 | 5,965 |
Total cash and cash equivalents and investments | 14,006 | 5,965 |
Level 3 | ||
Fair Value | ||
Cash and cash equivalents | 0 | 0 |
Short-term investments | 0 | 0 |
Total cash and cash equivalents and investments | $ 0 | $ 0 |
Supplemental Financial Information (Details) - USD ($) $ in Thousands |
Mar. 31, 2024 |
Dec. 31, 2023 |
---|---|---|
Inventories: | ||
Raw materials | $ 0 | $ 0 |
Work-in-progress | 84 | 100 |
Finished goods | 430 | 281 |
Inventory | 514 | 381 |
Accrued Liabilities: | ||
Accrued research and development services | 3,688 | 3,705 |
Accrued compensation and benefits | 6,493 | 9,591 |
Short-term lease liability | 1,291 | 1,291 |
Other | 3,860 | 2,570 |
Total accrued liabilities | $ 15,332 | $ 17,157 |
Commitments and Contingencies (Details 1) - USD ($) $ in Thousands |
3 Months Ended | ||
---|---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
Dec. 31, 2023 |
|
Commitments and Contingencies Disclosure [Abstract] | |||
Operating lease right-of-use-assets | $ 5,358 | $ 5,524 | |
Operating Lease, expense | 400 | $ 400 | |
Payments for rent | $ 300 | $ 100 | |
Weighted-average remaining lease terms | 8 years 10 months 24 days | 9 years | |
Weighted-average discount rates | 9.60% |
Commitments and Contingencies (Details 2) - USD ($) $ in Thousands |
Mar. 31, 2024 |
Dec. 31, 2023 |
---|---|---|
Commitments and Contingencies Disclosure [Abstract] | ||
2024 | $ 1,036 | |
2025 | 1,220 | |
2026 | 865 | |
2027 | 881 | |
2028 | 898 | |
Thereafter | 4,746 | |
Total undiscounted operating lease liability | 9,646 | |
Less: amount of lease payments representing interest | (3,276) | |
Present value of future lease payments | 6,370 | |
Less: short-term operating lease liability | (1,291) | $ (1,291) |
Long-term operating lease liabilities | $ 5,079 | $ 5,265 |
Equity Incentive Awards - Narrative (Details) - USD ($) $ in Millions |
3 Months Ended | |
---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Share-Based Payment Arrangement [Abstract] | ||
Share-Based Payment Arrangement, Expense | $ 4.3 | $ 3.4 |
Equity Incentive Awards - Summary of Weighted-Average Stock Options Assumptions (Details) - Stock Options |
3 Months Ended | |
---|---|---|
Mar. 31, 2024 |
Mar. 31, 2023 |
|
Employees | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Expected Volatility | 96.00% | 112.00% |
Risk-free Interest Rate | 4.30% | 4.10% |
Expected Term | 4 years | 4 years |
Dividend Rate | 0.00% | 0.00% |
Officers and non-employee directors | ||
Share-based Compensation Arrangement by Share-based Payment Award [Line Items] | ||
Expected Volatility | 104.00% | 98.00% |
Risk-free Interest Rate | 4.20% | 3.90% |
Expected Term | 6 years | 6 years |
Dividend Rate | 0.00% | 0.00% |
Equity Incentive Awards - Summary of Stock Option Activity (Details) - Stock Options shares in Thousands |
3 Months Ended |
---|---|
Mar. 31, 2024
$ / shares
shares
| |
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] | |
Outstanding at beginning of period (in shares) | shares | 18,705 |
Granted (in shares) | shares | 3,822 |
Exercised (in shares) | shares | (51) |
Expired (in shares) | shares | (148) |
Forfeited (in shares) | shares | (670) |
Outstanding at end of period (in shares) | shares | 21,658 |
Exercisable (in shares) | shares | 9,631 |
Weighted Average Exercise Price | |
Outstanding at beginning of period (in dollars per share) | $ / shares | $ 3.93 |
Granted (in dollars per share) | $ / shares | 2.16 |
Exercised (in dollars per share) | $ / shares | 1.72 |
Expired (in dollars per share) | $ / shares | 12.04 |
Forfeited (in dollars per share) | $ / shares | 2.21 |
Outstanding at end of period (in dollars per share) | $ / shares | 3.62 |
Exercisable (in dollars per share) | $ / shares | $ 5.03 |
Equity Incentive Awards - Summary of Restricted Stock Units Activity (Details) - RSU’s shares in Thousands |
3 Months Ended |
---|---|
Mar. 31, 2024
$ / shares
shares
| |
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] | |
Outstanding at beginning of period (in shares) | shares | 5,015 |
Granted (in shares) | shares | 8,270 |
Vested (in shares) | shares | (1,921) |
Forfeited (in shares) | shares | (297) |
Outstanding at end of period (in shares) | shares | 11,067 |
Weighted Average Grant Date Fair Value | |
Outstanding at beginning of period (in dollars per share) | $ / shares | $ 2.78 |
Granted (in dollars per share) | $ / shares | 2.15 |
Vested (in dollars per share) | $ / shares | 3.12 |
Forfeited (in dollars per share) | $ / shares | 2.32 |
Outstanding at end of period (in dollars per share) | $ / shares | $ 2.26 |
Other Capital Agreements (Details) - USD ($) $ / shares in Units, $ in Millions |
Mar. 11, 2024 |
Mar. 31, 2024 |
Dec. 31, 2023 |
---|---|---|---|
Class of Stock [Line Items] | |||
Preferred stock, par value (in dollars per share) | $ 0.01 | $ 0.01 | |
Common stock, authorized (in shares) | 450,000,000 | 300,000,000 | 300,000,000 |
Private Placement | |||
Class of Stock [Line Items] | |||
Net proceeds from sale of stock | $ 242 | ||
Number of common stock shares issued for each preferred stock share upon conversion | 50 | ||
Shares issuable | 115,000,000 | ||
Series A Preferred Stock | Private Placement | |||
Class of Stock [Line Items] | |||
Shares sold | 2,304,147 | ||
Preferred stock, par value (in dollars per share) | $ 0.01 | ||
Price per share (usd per share) | $ 108.50 |
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
YK1UI^?'!H$6BYJ\)I$<%@HU.>)7
M&A;V5T=98H/ =9O^5B./V#F+9IC:(BG/V(!LY;F8]]U$$$1FY48@WK$T*$Z3
MXW=.F(J!M:Y( G;#?ZW6(>\H&U>I5"\T;/CT^\V'CY>BQ(QQ,H>KY$%=>IV+
MR\KBW\DA=_MA(BXAKZP=-BU49T]6<\!)"124K2DB,Y!6&A]LI.^+&EMD86HJ
MOI4J>[Y00&Q8%$(0W6ZRLW@A*MK]5$"&5+/_PM2AHNSJFU=@M8/]0]HMRP?A
M,>!0QQI"L9C]NZ^TY3ZE&-(;S=WF_+XIT0*5PNILJ[P.!=*-/DBMGB-P#Q/8Y \BJ;IGXCTR@??_TLM
M?*H-J-]HY=-+'[FQ_JY.1^-IS#(ET6(YR+0<)XLIRW1$7Q"V5V1\G$"F-$)S
M[$B2'"]8DC3Y$TGB>#R=+[R?9$XOG3DF.V?$2IJ-/PGSUTQ;NW!<')X.A^W+
M<,9\6AY.ZO"]44AO*=
9'H>TG7.E&Y;CTJ/6T*AVZ*V>/XNFX>LSA-.!<'H.??78-0S(#9PX
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ML93*O#*H:N!BA]ITQQ6GF1_.9Q"E/KW=@UN K38=N0%SNWG=2*%Y4B>T $9L DY0P)6$^M&;Z>XY$Q*$;\0^$@&^_(A++B_-XT/B93
MRS5$D$*LC NB'WNX@30UGC3'MZ-3JYK3?3]X_%,'K8%9$P@U/O]!$;:?6
MR$()K,DN57?\\"<< PJ,OYBGLOA%A^-8UT+Q3BJ>'8TU0499^20/QT0T#'RO
MP\ [&G@%=SE10?F>*!)-!#\@849K;^:E"+6PUG"4F:^R5$+_2[6=BFZ_[:AZ
M1!]9#,SD!\T.1"027:%E^9T07Z.EXO$]^IP7>9R9/!J;U^]!$9K*-V9P8X1$
M -8?20$3;8T.P6BP^0"X99K>]9!:G$7II9]-
MH_]0I6A*Q2'/BQYQS"2Z#/TPGL*QYR(8/>\UJJT;8AIRV0K3O?3#[C GK[OQ
M\,.\&[)T&;=<:&JA#;F&DTL:2ZH;7-W"R,8-B[4T-'J<6-*L1V4-2+^1TAP6
M-L#P[V'U'5!+ P04 " -@:)8-<>;>F # #.!P &0 'AL+W=OL
..N]S328O;&GD@]Z3AGEBYOV6@2_5&
M@>BCGW3H1_&H_7Y:)QB(/VWPIW9\KC!%!5OK+9473,$:Z79$8+/;(@JZ&"-*
M\(I0HN[[#$X[!J=1QZ 58:!!WWNLII[5XF>0\@+AW-A#?%.[VN'[JKP(*&&?PJF7XQ@]\QP](XNIKK(DG0#<_T
MRI&DS)D0A&U 5[-"JT?4'+<@CT5WD?>WIQ3JEYV22F>.L@WZ]XZG*=)5:,9\
M;4MER35HYS(K^UKF)(:II9>N!+$'*_K]-QRZ[WJB'E11#_J\1TU2HN.##67,
M-'3EY" H3]!K70IEEM^@_UKS78913A04$QD]V4=X-'2#B;-OX0LJOJ"7[P^=
M>P7/APC.(/R1Y[4SA!5#V,MP^P BIO(%%.$9Q56 VR&&%<3P!Q Y%2] &)XC
MX,&HG6%4,8QZ&701KX&^Y'.,SBG"H=M.,:XHQB\I66#)!<4Z/@/S[
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MUAB)4EAK4]<>Z@H3Y56@;"B>%\?O%5?Z,%^\;O7U"809H/]?
T9PM;'^1
MMP8P]2ZN3JJ*+S]R5HB2NLD?G' T("M>,).*_3+9H%2F)D!5Q3I=ET,_)3
MD>J1+O2JG!8Y[KEW@I[_[CH75%!%^*9I4_O'O,JO=AS?_"O+]K?*KF&OQ^;5
M>^PFKT_!9'(*)D^B)ONG8#(]?I/Q<7J,FD/&QDEFZQS31@,X+P[#;W#ZY.ND
MP63.N&:BZ
>V$P#//0^F52HF\B+$9=[E#
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M'8=SC0$&<=PR0RPB; P?NJL5H5FAH9 \J"*G.(U@"5EA=A) @1Z!'HX:+J+'>:MLV7ICVO*P7YY(2IB>Q.@3>0
MTL9!&(\!NK*HG]8$NG7Q#@C>P+EW8+)3WC4X)Y9=D6':V1 U37K<+;+DM>\3
M]YE5>/HTF0VY)Q/\Z/J5^-9\,NJM&_-L81[%C.BZJAA<%Y06U+>C;[:)]% T
MQ 3T.?(Q3,^(B$G[?++\PV>]I;-TU 4Z$C14$1K:S284Z!'H$>@IFLB0"8^M
M2V0H11;K 1.'J1S()3B 867AC?=;KY!"^8=_!J(EG[3>O.S
MG7.&BAS?#;;>-G6G1ZW<;+5EN*7$(&]C.K-(5BA^,L[-&BT+68A.6_)C@Q_B
MRAVS]D%#H12OET+GJ#Q 5^%D44QM91>HS'8KYP M;T)<^^$<"V"UF82M8'
M_L=[X3OW9$6(M4KA'G03,CF<.P510.U*)5%I!=%9JR!>Q .D6/O-M6(OAC*!W*P
M/H4QA\CT#SC/Y!WH53CBFREX'94< +DC3^#F?'.G?M%.C4K%8W"'7A N8@[
M*&P8KZGH;J7W-E*PV1:\J+=[;:H\F1$:"55WA=IJSMJ*'$0K;K6+JM%L0CC\D1*&[WW$DE)D;'==5U6L\4N>2*E"BKL
M? .FV@K[D3KPX7-=>J8NQ:M9J-2(-;)=.PA]=@'I(+J[U*D!PQ6,66.SZ#8((FH5SL%HQS>)U)R;1-7HV'"8S.TYG
M%L/-G,'P0,&$#.R0/E+_Q3;I/6S&LQZHZ3V[["TL>;RPM6C4>JVZ)JN
7'P.!4"*#EN2#"4OCK>:\#]?M[=NB#HO C>807O^5_N3Y=$
ME@T@WVJM/)$T4[,SN \D
MC'SFA94AHB_7UBE30OL>T+(5? 5_^1%8)4'1!(R<&\]Q*)L@N!OLPW'M6J^M
MU65NSE,%@1TQ]?48!(:G]4I=E<_RNG:%#FW>):
"T!?3I%."0AP& "BY'HVYB:C&23>2>4^,E,
MG^%MHS[U%R=K2E]AZ"#RL?C(/#KK$BOEEU):+@\L8AS?0&%X"@_DASG1H+0_
MXA,@LA !8P\=7A=G'TF*W/BOK9>L 98!L+8# QB/,5K_
2@$I.
M@L[=4@A$YDT)XOIN3'U0G^[S-\1(RE^37;D+4Q_KZO[
C 0+<1(F@A%MU
MDT@B@5[.?G[GG(N-Z_Z#;D.XE^QQ*,/H"_F.!O1WTG]D8Z*K3_$6M!)Z"YC^&
M251$\BT@^<$SFZ%;=9(?U&+^24C>NRN4\FT@^6%915,MY1]AVMU41(+0J;6L
M?VS"O\1C3JE_)[._V^RC6VK2(5
M76R'9]K65&5R<='"Z]9E^=9EK4JU+BNW3HYFAVRN*,SHH:RZ SF "F1&'"<[
MN2C%=)N;N96;I<73MEBQJ(]XP3QAO<_#!KAA8)S,^'6R^=:O8NPDL2@4!EII
M9=>)GA@V_4.A""G68Z#7"IP.@2Q1A1D,ED)!8
MSLU=?3Q6WC27# R)D+S.0&"J$IQ8'/(D=;6#%HO'A9#P#1^GG3GH6^C>GYE+
M1G.E^"3E%7P$-3)/(I '0K:(91M&SX8IIYELIX!82"\X-IH)QSS7>G$?6M-P
M%J*2")/8PDC0'+ZOK20]/X[Z&H-#=*[,&5X\=T+F1D;$;B.!$_I"65P-%A^G
MT8V[-V^,IL"APM3MDV2O8Q]N.,YT@OM/N(DPPF 1DK]#TV5B-I?4E68;,>DG
M37BT'PW/H0W:EO5!?>HN1,E,];5>G+4.I^D;S4\5JTB^ !XSN$_[.6!:X28^
MSH;,>YSDL)%S\IF/[;_@UNFT+].C+"ZJ[K;:JRY9J[WJFF;KFE=JX,T[H[X#
M^N*R0D!-4Y:'M*,)]+JL#UZ)3*>-/'GU\=#N]5N[5A_W6G:GO5OUYWN
M8>J86_:P/ZS8HH9VOU6U-0WLB\[Z>N]CG-.PU7](#7I%"Z4?6!>N=M7$/967
MUE=T\\55XEI9_9=60R_T)+YX\??S"2H5/8 4FZ.\T-/0=(&M<%[H&;S'Q ^8
M%N0/KM#"_B*P5H3)R*B@ KG"K/O M41QZ#UF[2B""S 0T33ML"
M<\/5W")+,I^"(&$VDL+^HI<5S>R\H\A!84/_EN9*NDB0WI+I;P4VGKFD113.
M*&7[')4SC\<$V1@OD&6R$M*+<<>P,*4)4(8JFCI%-OJL-'1+'T4!'^64LAKU
MZXQ!G("I+)3(":.XF"KH >1H$D6T&YUFM]'J7N1HXX;O[1+<\( 8 <_]6IN:
M-VQJHKY)Z0/$[,#N&9XPC0;5MJ8<^#F&U]-K!EC&I?T%";FJ06